AscendingBio (@AscendingBio) header
AscendingBio (@AscendingBio) profile picture

biotechnology stock investor

USA
Joined January 2025
Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)Photo by AscendingBio (@AscendingBio)
I aspire to identify stocks that can be purchased now and held for a year to achieve long term capital gains. I seek to identify stocks that will at least double in value. I encourage you to consider these stocks yet do your own research before investing.
1
2
28
15,399
$ACOG Looking At PBM Coverage The company reported, "Medicare Part D contracts in place with two major PBMs covering approximately 45 million lives. These contracts establish potential favorable access parameters as downstream implementation expands." So, I sought to take a closer look at what growth might be possible with adding other PBMs. First this context: Total U.S. Medicare enrollment is 70.7M. About 57.3 million (81.1% of the 70.7 million) are enrolled in Medicare Part D. About 56% of Part D enrollees (nearly 32 million people) receive their drug coverage bundled with a private Medicare Advantage plan. So, that means that about 38.7 million have public Medicare and enroll in Part D coverage. I found this breakdown of PBMs. It is somewhat dated, but it works for ballpark numbers. PBMs U.S. Medicare Part D Proportion CVS Caremark (Aetna) 33.4% 19.1M Optum Rx (United) 27.7% 15.9M SS&C Health 16.25 9.3M Express Scripts (Cigna) 15.4% 8.8M MedImpact 1.11% So, the numbers do not add up well here. Together, CVS Caremark and Optum Rx appear to cover 35M lives with Part D (61%). To get to 45 million, we need to include a company like SS&C Health. If we take the 57.3 million in part D and subtract out 45 million, that leaves 12.3 million that $ACOG can still add. That is probably the key number. (I know drug companies are quite careful about the information they provide about PBMs so that they do not offend the PBMs. PBMs hate transparency.) pmc.ncbi.nlm.nih.gov/article… data.cms.gov/summary-statist…
1
415
$CRDF Clues about Funding the Phase 3 As expected, no definitive statement was given today about the status of seeking funding for the phase 3. So, we are left to read between the lines. It was stated, "We are working earnestly to get our stage 3 up and running in some shape or form - even in a staged manner in the first quarter of next year." They have cash of about 34 million. Which is sufficient to fund operations through end of 3Q 2027. They seem to be asking all company leaders to act as if phase 3 funding is coming. That might mean initially opening a small number of sites and treating a limited number of participants until funding arrives. Presumably, they are actively meeting with potential partners. These negotiations do not happen in public. We wait and that could continue into early January. Some partners may need to wait until the start of the new year to sign a deal.
6
599
$AQST Looking Ahead to Payer Coverage. A key message being given to PBMs is: Cover Anaphylm and we will save you money on emergency care. Quotes from today's presentation relating to insurance coverage: "So one of the key things that we're focused on right now as we lead into our launch is making sure that we are talking to the payers. . . And so from our perspective, one of the core things for the payers to understand as our product comes forward is that we do have clinical differentiation, and as I mentioned before, that HEOR (Health Economics and Outcomes Research) data showing them that— making sure first they understand what their urgent care and ER spend looks like in this space, and then showing them the potential of what we can do with that with our product." "In fact, 60% of the time when someone has an allergic reaction they do not have a rescue medicine with them." "One of the key arguments we have . . ., especially with payers . . ., is we have an HEOR argument around the costs they are incurring with urgent care and ER visits."
1
15
789
$AQST Update on Anaphylm beyond the US Dan stated today, "We have a filing in Canada that will be before the end of the year. We'll be filing in Europe in the first quarter. We'll be filing in the UK in the second quarter. And we are in discussions with multiple companies. I actually see some of them here today, on potential partnerships outside of the US, but as of today, we are still in the process of determining the right company for our strategy, and more to come on this as time goes on." (No changes to the Canada and EU timeline, but new info for UK and other markets.)
2
1
13
1,069
$AQST It's Almost That Time There was plenty of information in today's presentation, yet no clues about FDA timing. Dan continues to express very high confidence that the FDA will respond to the resubmission with approval. My best guess is that Anaphylm gets approved in early January 2027. Yet, it is important to keep in mind that a December approval is possible. So, we are very close to entering the it could happen any day zone. (Keep in mind that the FDA can go a slow as they want. Yet, the amount of work required by the FDA to approve this drug is minimal. They need to have the stats team review the new data. The company said they have responded to FDA clarification questions. Those have likely included questions about the new data. So, the stat team may be done by now. Somewhere in the process, the team that looks at manufacturing issues will need to signoff that they are satisfied with the revised documents and the most recent plant inspection. Then, they ask: Have the identified concerns about the ease of opening packaging and administration errors been addressed? In my opinion, the only reasonable answer is "Yes." Writing the product documents should go quickly. They start with the Neffy text and substitute Anaphylm specific data. There is so little to do here that even a January approval means that there have been periods of inaction. Progress can stop pause when a team turns its focus to another drug.)
1
1
22
1,299
$CRDF Quarterly The quarterly was posted today. As expected, no big news. "Cardiff expects to initiate the Phase 3 trial in the first quarter of 2027, subject to securing additional financing. In preparation, the Company is establishing key vendor relationships for trial execution and clinical supply materials, as well as finalizing the companion diagnostics for RAS mutational status." Next opportunity is an Investor conference on November 16 at 2:40 p.m. GMT. That is not the context where they would make an announcement about funding. Yet, there is always the possibility of a vague and subtle statement about how negotiations are progressing. investors.cardiffoncology.co…
2
519
$BCTX Bria-OTS/OTS+ All eyes are on the phase 3 results. If the interim results fall short of the target, it will be about another year until the next data readout. So, what other data is expected in 2027? Work continues on the next generation treatments known as Bria-OTS/OTS+. We can expect some form of a data release in 2027 related to the ongoing phase 1/2a studies. Today, the company mentioned the possibility of submitting these results to AACR which meets April 2-7, 2027. Yet, they have not ruled out issuing an earlier press release about initial responses to these treatments.
1
341
$BCTX Update In a presentation today, company leadership continued to indicate that the interim readout for the Bria-IMT metastatic breast cancer phase 3 could happen before the end of the year. It is also quite possible that this does not occur until early 2027. The interim data analysis occurs after reaching 144 mortality events (patient deaths). So, it is clear that they are quickly approaching that number, but it has not been met.
332
$KURA Comments related to J&J Drug "I know this is a question probably in a number of people's minds. And I'd say this, you got to put that headline in context. You know, J&J is third to market. They've got to make some noise, right? They're coming a year behind two entrenched incumbents. And so they're going to present the data that's in their best interest. But, there's a lot of questions. A third of the patients are missing from the efficacy calculation. So the efficacy evaluable is about 100. The ITT is about 146. You have to ask yourself, like, why are those patients not included? Were there deaths? Did they come off early? You know, what's going on? We've seen this with other companies even in the past several days. They clearly see differentiation syndrome. They clearly see QTC prolongation. And we all know the FDA is going to use an ITT analysis. So, you know, we look at that as that's an abstract. We don't even really know what the data is yet. But, you know, it changes nothing from our perspective." You asked about, you know, how do we grow? How do we continue? We anticipated this. We anticipated they would get here and we anticipate that they'll file. That's why you see us pushing toward frontline. It's why you see us pushing into combinations. We're the only menin inhibitor that will show you clinical data on not just one, but both of— or 2 out of the 3 approved FLT3 inhibitors. Nobody else can show that." And we know we hear it from physicians. I know all of you analysts and investors hear it on your doc calls. The future is combinations. The future is frontline. So this doesn't really— and we don't see, you know, if I would, as Molly said in her prepared remarks, We put our data up against anyone. We put our frontline and our combination data at this point up against any of our competitors. I think we feel like we offer the best benefit for patients. We offer the broadest potential range of mutations. So it really doesn't change anything at all except we're just heads down executing. Commercially, from a development perspective, and continuing to push out the frontier." "I'm going to ask Brian to comment. You know, this is AML. These physicians are very sophisticated. It's a small community. They study the literature. They're data-driven. You know, they work off of empirical evidence. For those who've been with us now for several years, this has been our strategy from the beginning. "The plan was to demonstrate that Zyfto had ideal safety, tolerability, combinability, and once-daily convenience and could be part of any backbone. And so that's what you're seeing us do is execute study by study, combo by combo, so that when a physician says, I want to use this particular regimen, there's already data out there, potentially a publication to support it. How come Zifty might drive better outcomes? That's been, you know, overarching. That's been the strategy. I think, you know, to Lee's earlier question, that's what distinguishes us, for example, from our competitors." "You look at that J&J abstract and you've got to sort of stop and think about the myelosuppression that you're seeing in that abstract. Is that going to be problematic in combination with Ven-Aza. You know it isn't from us because you can see both the Ven-Aza and the Frontline data." "But there's certainly an enthusiasm from the community to be able to learn about these data, particularly when it's unique that no other MENIN inhibitor is demonstrating combinations with FLT3s. That's a compelling argument for many."
4
6
3
43
10,482
$COYA Quarterly Report There is no big news in today's report. We did learn that they enrolled 137 participants in the Phase 2/3 ALSTARS trial of COYA 302 for the treatment of ALS. The original target was 120. Topline results are expected "Early Q2 2027." In prior calculations, I estimated April 26. 2027 at the earliest. I am going to take "Early Q2" as meaning during mid to late April. My guess is that they wait for these results before they start the Phase 2 study evaluating COYA 302 for the treatment of FTD. They indicate this will start at some point during 2027. ir.coyatherapeutics.com/news…
344
$FATE Safety First Approach There are many different approaches used in CAR-T treatment of Autoimmune disorders. After recent patient deaths in clinical trials using CAR-T treatment of autoimmune disorders, the CEO of Bristol Meyers Squibb said, "Immune effector cell-associated neurotoxicity syndrome (ICANS) is a known, potentially severe neurological side effect linked to CAR-T cell therapy across both oncology and emerging autoimmune disease trials." There is an assumption here that the safety levels for blood cancer treatment with CAR-T should be fine for autoimmune disorders. There is tolerance for significant risks with CAR-T cancer treatment, because there is an imminent risk of death. In balancing efficacy versus safety, there is an emphasis on efficacy. With autoimmune disorders, most patients will not tolerate the safety risks that are standard in CAR-T treatment of blood cancers. Pretreatment chemo conditioning is one place where there is a key tradeoff between safety and efficacy. High levels of conditioning chemo gives a big bump to efficacy, but it comes at a significant cost to safety. Fate is a company that recognizes it needs to put safety first to reach the autoimmune market. For example, it would be better to have to give a few persons a 2nd treatment a year after initial treatment than to risk life threatening side effects. The path to the biggest market share in autoimmune disorders starts with safety. That means offering a no chemo conditioning option. The data presented today shows that reasonable efficacy is achievable without chemo conditioning. That is a really big deal. Fate has determined that the quickest path to market is with low levels of chemo. Yet, that is just the first chapter. It will soon be common to compare the efficacy of different CAR-T approaches to autoimmune disorders. For this market, those values should always be viewed in the context of safety which includes the strength of chemo conditioning.
1
3
753
$TGTX Recovery from the Dip Nice recovery from the morning dip. Plenty of good news today that should move this forward. If that was not enough, they do not hesitate to buy back stock. They purchased 100M last quarter and will keep looking for buying opportunities.
2
529
$KOD It seems that most make the assumption that "If Baker Bros is buying like this, Kodiak Sciences must be good." Very few are looking under the hood to see what the company is actually worth. In my assessment, the company is way overvalued. Yet, that is from doing the gritty work of looking at the data and evaluating the competition. I know all this buying by Baker Bros holds up the value of their prior investments. Well, really I should say the value on paper because if they wanted to sell these shares they would need to do so at a massive discount. Baker Bros now owns about 35% of the company. I am not able to come up with a scenario where Baker Bros gets out of this without taking a big hit. I would love to hear the Baker Bros plan. When can they start selling more than they are buying each day? There may be no plan. It may just be this is what we need to do today to protect our investment. Our investment is now worth 2 billion. We will figure out the exit strategy later. Maybe, it is just about making it to year end so the year end numbers look strong to their investors. Hopefully, the employee bonus plan does not highly reward building up value that is only on paper. This continues to be interesting to watch. Just how high can they build up this house of cards until . . .
$KOD Baker adds another $24.5 million dollars! Comes after massive add few months ago $XBI $IBB
2
470
$AQST Confidence about FDA Approval There was a clue in the quarterly call about the level of confidence of Aquestive leadership concerning Anaphylm approval by the FDA. They stated that they are now hiring district sales managers. I presume this is about 3 persons. I expect interviews for sales reps to start by December 1. For candidates that they like, they will probably inform them that they will be sending out offers within 48 hours of approval of Anaphylm by the FDA. If approval comes in late December or early January, they want to have district sales managers in place and be ready immediately to start building the sales team.
1
14
1,065
$DWTX Today's Big Gain There is no news driving today's gain (currently about 30%). This is returning to fairly recent price levels. Phase 2b results could be any day now. This stock is a high risk investment. Yet, the potential rewards are quite significant. The recent volatility beyond the market-wide issues yesterday are unexplained.
333
$SPRY $AQST Review of the SPRY Quarterly 1) Financials: -U.S. net product revenue for Neffy of $33.4 million for 3Q. -Third-quarter 2026 total operating expenses were $71.9 million. This included a one-time $12.5 million upfront intellectual property licensing fee for a new product that they have not disclosed. -Net loss for the third quarter of 2026 was $35.6 million. Reflections: They have made significant cuts to expenses by ending advertising. Next quarter will not have the 12.5M licensing fee, but this product will require research expense. I still do not see how they break even in 2027. It seems that would require significant growth in market share and reducing expenses to about 40 million a quarter. The options for further reducing expenses are to cut staff or research expenses. There is no indication they plan to do this. Just increasing market share by this time next year is not going to stop the cash burn. (If I am missing something here, respond and be specific about how you make these numbers work.) 2) Market Share: Total U.S. market share reached 5% in the third quarter of 2026, up from 4% in the third quarter of 2025. I praise them for declaring that product differentiation is key to growing market share. ARS reports, "So where our field team engages, NEFI wins." Physicians are responding to the sales teams. It was stated, "Only about 1 in 3 patients with an autoinjector prescription, carry it consistently, and roughly half delay or never use it during a reaction. This is an unacceptable gap, leaving patients unprepared and unprotected. A needle-free, easy-to-carry, and easy-to-administer device can close that protection gap and expand the market over time." That sales pitch carries some weight now. Yet, I do not see Neffy as being easier to carry than autoinjectors. Anaphylm is likely to get FDA approval in early 2027. The Neffy sales reps are making a pitch that best fits Anaphylm. What are the Neffy reps going to say in early 2027? For a short period of time, they will be able to say, "We have the insurance coverage." At the quarterly, it was said, "Prior authorizations are routine in allergy practices, including for the biologics these same physicians prescribe regularly. Because our representatives now engage the full care team, including the staff who manage PA submissions, we can make sure those offices have what they need to complete them. When they do, the majority of submitted PAs are approved." Once again, the Neffy reps are clearing a path for Anaphylm. They are training top prescribers that preauthorizations for epi rescue meds is not a big headache and is worth the effort. Anaphylm reps are going to present data to doctors that show it offers the fastest symptom relief during a severe allergic reaction. You add in the extraordinary portability and best stability under extreme temperatures and the competition has no counter strengths to offer except cost/insurance coverage. If cost/insurance coverage is what drives a prescription, Neffy will not win that market. That sale will go to a generic autoinjector. Neffy appears to have the highest device manufacturing/royalty costs in the market. It is not equipped for a price war. Anaphylm's very low manufacturing costs and lack of royalties means it could win a price war with the device-based products. Yet, its best in class product features means that it can demand a premium price.
1
9
1,282
$DWTX Results Coming This Month Dogwood announced that results will be released this month (November) for the Halneuron Phase 2b (239 patients). "Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron reduction in pain over three months of treatment with Halneuron." They closed a $5 million private placement to give them more flexibility through the first quarter of 2027. It basically buys time to explore funding options for a phase 3. Pain studies have major challenges due to placebo effects. They appear to have designed a solid study with a promising treatment, but what matters is the results when they turn the cards. ir.dwtx.com/news/press-relea…
286